Group-Sequential Methods for Adaptive Seamless Phase II/III Clinical Trials

By Stallard Nigel  

Journal of Biopharmaceutical Statistics, Vol. 21, Iss. 4, 2011-07 ,pp. : 787-801

Taylor & Francis Ltd

Access to resources Recommend Favorite

A Seamless Phase II/III Design with Sample-Size Re-Estimation

By Bischoff Wolfgang  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 4, 2009-07 ,pp. : 595-609

Taylor & Francis Ltd

Access to resources Recommend Favorite

A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer

By Renouf Daniel  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 779-786

Springer Publishing Company

Access to resources Recommend Favorite

Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer

By Satoh Taroh  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1511-1518

Springer Publishing Company

Access to resources Recommend Favorite

Effects of Varying Degrees of Renal Impairment on the Pharmacokinetics of Duloxetine: Analysis of a Single-Dose Phase I Study and Pooled Steady-State Data from Phase II/III Trials

By Lobo Evelyn D.  

Clinical Pharmacokinetics, Vol. 49, Iss. 5, 2010-05 ,pp. : 311-321

Adis International

Access to resources Recommend Favorite